EMERYVILLE, Calif.–(BUSINESS WIRE)–Radiance Therapeutics, Inc. (RadianceTx®), an innovation leader in ophthalmic devices, is delighted to announce that its CEO, Laurence Marsteller, MSc. MD, will be representing the company at the LSI USA ’23 Emergin…
Author: Business Wire
LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for …
LumiThera annonce une amélioration soutenue de la vision pendant 24 mois chez les personnes atteintes de dégénérescence maculaire liée à l’âge sèche à partir des données de l’essai clinique LIGHTSITE III aux États-Unis
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., une société de dispositifs médicaux offrant un traitement par photobiomodulation (PBM) pour les lésions et les maladies oculaires, annonce aujourd’hui les données à 24 mois de son essai clinique multicentrique …
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
BOSTON–(BUSINESS WIRE)–Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the fou…
LumiThera meldet anhaltende Verbesserung des Sehvermögens nach 24 Monaten bei Patienten mit trockener altersbedingter Makuladegeneration (AMD) bei der in den USA durchgeführten klinischen Studie LIGHTSITE III
SEATTLE (USA)–(BUSINESS WIRE)–LumiThera Inc., ein Medizintechnikunternehmen, das Photobiomodulation (PBM) zur Behandlung von Augenschäden und -krankheiten anbietet, gab heute die 24-Monatsdaten der multizentrischen klinischen Studie LIGHTSITE III bek…
Resumen: LumiThera anuncia una mejora sostenida de la visión durante 24 meses en sujetos con degeneración macular asociada a la edad seca a partir de los datos del ensayo clínico estadounidense LIGHTSITE III
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., una empresa de productos sanitarios que ofrece tratamientos de fotobiomodulación (PBM) para lesiones y enfermedades oculares, ha anunciado hoy los datos de 24 meses de su ensayo clínico multicéntrico LIGHTSITE …
Samenvatting: LumiThera kondigt een aanhoudende verbetering van het gezichtsvermogen gedurende 24 maanden aan bij personen met droge leeftijdsgebonden maculadegeneratie, op basis van gegevens uit de klinische LIGHTSITE III-studie in de VS
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., een medisch bedrijf dat fotobiomodulatie (PBM) aanbiedt voor de behandeling van oogschade en -ziekten, kondigde vandaag de 24-maands gegevens aan van haar LIGHTSITE III, een multicentrum klinisch onderzoek dat …
Riassunto: LumiThera annuncia un miglioramento della vista sostenuto per 24 mesi nei soggetti affetti da degenerazione maculare secca legata all'età grazie ai dati dello studio clinico statunitense LIGHTSITE III
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., azienda di dispositivi medici che offre trattamenti di fotobiomodulazione (PBM) per danni e malattie oculari, ha annunciato oggi i dati a 24 mesi dello studio clinico multicentrico LIGHTSITE III, che ha dimostr…
LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-month data from its LIGHTSITE III, multi-center clinical trial which demonstr…
GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
IngenioSpec Introduces Text and Voice Technology for Smart Eyewear
SAN JOSE, Calif.–(BUSINESS WIRE)–IngenioSpec adds text and voice technology to its list of patented technologies for smart eyewear.
Be My Eyes Announces New Tool Powered by OpenAI’s GPT-4 to Improve Accessibility for People Who are Blind or Have Low-Vision
SAN FRANCISCO–(BUSINESS WIRE)–Be My Eyes, the mobile app that allows anyone to assist visually impaired people through live video calls, today announced Virtual Volunteer™, the first-ever digital visual assistant powered by OpenAI’s new GPT-4 languag…
CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations
SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics today announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations
New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic nerve lesions in people …
Eyeganics Organic Tears, the Only USDA-Certified Organic Lubricant Eye Drop, Now Available through NovaBay Pharmaceuticals’ Avenova.com and Physician-Dispensed Channel
EMERYVILLE, Calif. & KIRKWOOD, Mo.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces a partnership with Eyeganics to sell OTC Organic Tears (0.2% organic glycerin) on Avenova.com and through Avenova’s physician-dispensed c…
Harvard Study Shows E Ink’s ePaper Is Up to Three Times Healthier for Your Eyes Than LCD Screens
BILLERICA, Mass.–(BUSINESS WIRE)–E Ink (8069.TWO), the originator, pioneer, and global commercial leader in ePaper technology, announced today the results of a peer-reviewed study about the effect of displays on human retinal cells, commissioned thro…
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status f…
Morocco Eyewear Market Report (2022-2028): Rising Screentime Amongst Adults and Children Bolsters Demand – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Morocco Eyewear Market (2022-2028) | Size, Trends, Growth, Revenue, Analysis, Forecast, Value, Industry, Outlook & COVID-19 IMPACT: Market Forecast By Product Type, By Distribution Channel, By End Users and Competitive…
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announced new data on the use of TEPEZZA (teprotumumab-trbw) in patients with dysthyroid optic neuropathy (DON) at NANOS 2023.